Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Oxford is teaming up with four Berlin institutions, the Freie Universität Berlin, Humboldt-Universität zu Berlin, Technische Universität Berlin, the Charité – Universitätsmedizin Berlin, creating a new partnership which will open up exciting new initiatives across all academic disciplines.

Image courtesy of Shutterstock

The five universities will build on their strong existing research links and also create an environment for forging new projects in medicine, the sciences, humanities and social sciences. The agreement takes longstanding research relationships to a unique institutional level, marking the first common agreement of all four Berlin institutions with an international partner.

Under the new partnership, Oxford academics and researchers will have a platform to spend time in Berlin, collaborating with colleagues in the Charité teaching hospital, and the three Berlin universities, as well as the many other research institutes within the Berlin-Brandenburg region. At the same time, there will be support for academics, researchers and students from Berlin to spend time in Oxford’s departments and colleges.

Read more (University of Oxford website)

Similar stories

General anaesthesia should be available for dying patients - medical and ethical experts

General Research

General anaesthesia should be more widely available for patients at the end of their lives, according to Oxford experts in ethics and anaesthesia, according to a paper published by Anaesthesia (a journal of the Association of Anaesthetists).

Risk of rare blood clotting higher for COVID-19 than for vaccines

Coronavirus COVID-19 Research

COVID-19 leads to a several-times higher risk of cerebral venous thrombosis (CVT) blood clots than current COVID-19 vaccines.

Asthma drug budesonide shortens recovery time in non-hospitalised patients with COVID-19

Clinical Trials Coronavirus COVID-19 Research

Inhaled budesonide, a common corticosteroid, is the first widely available, inexpensive drug found to shorten recovery times in COVID-19 patients aged over 50 who are treated at home and in other community settings, reports the PRINCIPLE trial in 1,779 participants.

Link between COVID-19 infection and subsequent mental health and neurological conditions found

Coronavirus COVID-19 General Research

One in three COVID-19 survivors received a neurological or psychiatric diagnosis within six months of infection with the SARS-CoV-2 virus, an observational study of more than 230,000 patient health records published in The Lancet Psychiatry journal estimates. The study looked at 14 neurological and mental health disorders.

New national study of long-term impacts of debilitating lung damage from COVID-19

Coronavirus COVID-19 General Research

A new national study will investigate the long-term effects of lung inflammation and scarring from COVID-19. The study, launched with £2 million of funding from UK Research and Innovation (UKRI), aims to develop treatment strategies and prevent disability.